LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- NOTICE TO THE HOLDERS OF: EUR 200,000,000 EURO FIXED RATE ENHANCED CAPITAL ADVANTAGED PREFERRED SECURITIES ("LP IV ECAPS") ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING IV LP ("LP IV") ISIN: XS0282978666 LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP IV ECAPS THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE SUBJECT SECURITIES. IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND ...

The new moisturizer stands beside Honest's award-winning Hydrogel Cream to build the Hydration skincare portfolio, now with up to double the hours of deeply moisturizing hydration for the faceUltra-Rich Moisturizer: Clinically tested for dry to extra-dry skin, delivering up to 48 hours of hydration.Honest Clean Conscious™Formula: Made with toxicologist-audited ingredients, hypoallergenic, dermatologist tested, vegan, cruelty-free, EWG Verified® and made without fragrance. True to The Honest Standard. Capti ...

Core Insights - Obagi Medical has launched two new lip products, the Obagi Lip Therapy AHA + PHA Smoothing Micro-Peel and the Obagi Lip Therapy Soothe & Protect Lip Treatment SPF 30, as part of a targeted treatment protocol for lip care [1][2]. Product Details - The Lip Therapy protocol is designed for nightly rejuvenation and daily protection, focusing on the delicate lip area to improve texture, restore hydration, and protect against environmental stressors [2][5]. - The AHA + PHA Smoothing Micro-Peel features three resurfacing acids: Glycolic Acid, Lactic Acid, and Gluconolactone, along with Hyaluronic Acid and Argan Oil to enhance moisture retention and improve lip appearance [3][4]. - The Soothe & Protect Lip Treatment SPF 30 provides hydration and broad-spectrum sun protection, formulated with a plumping peptide complex, Calendula, Hyaluronic Acid, and Vitamin E to smooth fine lines and support the lip barrier [4]. Consumer Feedback - In consumer perception testing, a majority reported smoother, plumper, and more replenished lips immediately after application, with continued improvements in hydration and overall appearance within two weeks [5]. Company Background - Obagi Medical has over 35 years of experience in advanced skincare, initially recognized for its treatment of hyperpigmentation with the Obagi Nu-Derm® System, and is now the fastest-growing professional skincare brand in the U.S. as of 2024 [7]. Availability and Pricing - The Lip Therapy AHA + PHA Smoothing Micro-Peel is priced at $55, and the Soothe & Protect Lip Treatment SPF 30 is priced at $40, both available through professional channels and on Obagi.com starting February 3rd [6].

Group 1 - LHV Group is hosting a webinar on February 10 at 12:00 p.m. EET to present its financial results for Q4 and the full year of 2025 [1] - The webinar will be conducted in English and will allow participants to ask questions at the end of the session [1] - The recorded webinar will be available on LHV Group's website and YouTube channel [2] Group 2 - LHV Group is the largest domestic financial group and capital provider in Estonia, with key subsidiaries including LHV Pank, LHV Varahaldus, LHV Kindlustus, and LHV Bank Limited [3] - As of the end of November, LHV Pank serves 489,000 clients, LHV's pension funds have 106,000 active clients, and LHV Kindlustus protects 230,000 clients [3] - LHV Bank holds a banking license in the UK and provides services to international fintech companies, as well as loans to SMEs and retail banking services [3] Group 3 - The Investor Relations team includes Sten Hans Jakobsoo as Head of Investor Relations and Corporate Development, with contact information provided [4] - The communications team is led by Paul Pihlak, with additional key executives listed including Mihkel Torim (CEO), Meelis Paakspuu (CFO), Kadri Kiisel (CEO of LHV Pank), and Erki Kilu (CEO of LHV Bank) [4]

Core Viewpoint - Middlefield Limited has launched the Middlefield Short Duration Bond Plus ETF, which aims to provide absolute returns through interest income and capital appreciation while maintaining a low risk profile and reduced volatility [1][2]. Group 1: ETF Details - The ETF, trading under the ticker symbol MSBP on the Toronto Stock Exchange, focuses on short-duration U.S. and Canadian corporate fixed income securities [1][2]. - The portfolio is managed with a targeted duration of less than 2.5 years to mitigate interest rate risk and may utilize various fixed income instruments and risk management tools [2]. Group 2: Management Team - The ETF will be managed by Gordon McKay, who has 20 years of experience in high yield debt as an analyst and portfolio manager [3]. - McKay holds a Bachelor of Commerce degree from the University of Alberta and is a CFA Charterholder, recognized for both athletic and academic achievements [3]. Group 3: Company Background - Middlefield, founded in 1979, is an income-focused asset manager with offices in Toronto and London, specializing in identifying attractive investment opportunities while evaluating associated risks [4]. - The company offers a diverse range of investment solutions, including Exchange-Traded Funds, Canadian Mutual Funds, and other investment vehicles, focusing on sectors such as Real Estate, Healthcare, and Fixed Income [4].

Core Viewpoint - Great Elm Group, Inc. is set to release its financial results for the fiscal quarter ended December 31, 2025, on February 4, 2026, after market close [1] Group 1: Financial Results Announcement - The financial results will be announced after the market closes on February 4, 2026 [1] - A conference call and webcast will be held on February 5, 2026, at 8:30 a.m. Eastern Time to discuss the financial results [2] Group 2: Conference Call Details - Interested parties can participate in the conference call by dialing +1 (877) 407-0752 for domestic calls and +1 (201) 389-0912 for international calls [2] - Participants should enter Conference ID 13757471 if prompted [2] Group 3: Company Overview - Great Elm Group, Inc. is a publicly-traded alternative asset manager focused on a diversified portfolio across credit, real estate, specialty finance, and other alternative strategies [4] - The company manages Great Elm Capital Corp., a publicly-traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust [4]

Group 1 - The Board of Directors of MBAK Energy Solutions, Inc. has authorized a stock repurchase program of up to $500,000, which will be funded through existing cash reserves and recent order fulfillment payments [1][2] - The company expects to initiate the buyback immediately and continue throughout Calendar Year 2026 until the target amount is reached [1] - CEO Dietmar Schweizer emphasized that the current valuation does not reflect the aggressive growth anticipated in the 2026 guidance, and the buyback demonstrates a commitment to shareholder value [2] Group 2 - The stock repurchase program follows several operational milestones, including a ticker symbol change, new board leadership, and an expanded focus on energy storage and management products [2] - The company has fulfilled production orders worth $65 million in the order pipeline for 2026, indicating strong operational performance [2] - The $500,000 buyback target represents a significant percentage of the company's current issued and outstanding shares, adding price support and stability [2][3]

Core Insights - Inspira Technologies has successfully validated its Next-Generation Standalone HYLA™ System, which is designed to operate independently of its existing respiratory support devices, allowing entry into the $50 billion heart-lung surgery market upon clearance [1][4] Group 1: Product Validation and Performance - The HYLA™ optical sensor achieved a 94.2% accuracy in tracking the Partial Pressure of Carbon Dioxide (pCO₂), aligning with clinical needs and demonstrating concordance with gold-standard blood gas analyzers within a 7 mmHg threshold [2][3] - This system provides continuous, non-invasive monitoring of a patient's metabolic status, potentially reducing complications during heart-lung machine and ECMO procedures by eliminating the need for intermittent blood draws [2][3] Group 2: Strategic Market Positioning - By decoupling the HYLA™ sensor from existing life-support hardware, Inspira Technologies is advancing a standalone system that can integrate into any operating room or ICU workflow, significantly expanding its total addressable market [3] - The company is pursuing a high-margin, recurring revenue model through the sale of disposable optical sensors and modular software upgrades, enhancing its long-term growth prospects [3][4] Group 3: Future Plans and Industry Engagement - The CEO of Inspira Technologies indicated that the validation confirms the technology operates at a clinical grade, enabling faster market entry and serving a large global installed base of perfusion systems [4] - The company is moving towards a planned FDA regulatory submission process in 2026, focusing on extracorporeal procedures as an immediate commercial opportunity [4]

Core Insights - TIAN RUIXIANG Holdings Ltd has entered a strategic agreement with a global digital asset investor, involving the injection of 15,000 Bitcoins in exchange for equity, enhancing its position in AI and cryptocurrency [1][2][4] Financial Impact - The Bitcoin infusion represents a significant addition to TIRX's balance sheet, strengthening its financial position and resilience while unlocking substantial shareholder value [2][4] - The transaction is expected to accelerate TIRX's product R&D cycle and expand its global market reach [4][6] Strategic Partnership - The partnership will establish a joint global innovation lab, focusing on AI-powered cryptocurrency trading systems, blockchain infrastructure, and new AI-crypto fusion products [3][4] - The collaboration aims to leverage TIRX's AI capabilities and the investor's crypto market insights to create a competitive advantage in the evolving landscape [3][4] Market Positioning - TIRX aims to dominate the convergence of AI and cryptocurrency, positioning itself as a leader in the integration of these technologies [4][5] - The company is committed to driving mass adoption of innovative digital finance solutions globally [4][6]

-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe --ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland. The agreement includes FemBloc Permanent Birth Control, Fe ...